Alyssa Stetson,Roshni Dasgupta
Alyssa Stetson
The role of minimally invasive surgery (MIS) for ovarian neoplasms in paediatric patients depends on multiple factors. First, it is important to consider the risk of malignancy, which can be difficult to assess, especially in the setting of...
A prospective randomised comparative study of three palliative radiotherapy schedules in incurable locally advanced head and neck cancer [0.03%]
晚期头颈部肿瘤姑息放疗三种方案的前瞻性的对比研究
Shivani Malik,Ashok Kumar Arya,Renu Singh et al.
Shivani Malik et al.
Introduction: There are multiple dose fractionation schedules for palliative radiotherapy (RT) of patients belonging to incurable locally advanced head and neck squamous cell carcinoma (LAHNSCC), but none is accepted as s...
Abdelhafeez H Abdelhafeez,Sabine Sarnacki,Blanc Thomas
Abdelhafeez H Abdelhafeez
Objective: The aim of this guidance is to discuss the advantages of utilising adjunct technologies in minimally invasive surgery and to mitigate risks associated with these technologies in paediatric cancer surgery. ...
Peripheral T-cell lymphoma of the lip: a rare case unveiling key insights into diagnosis and management [0.03%]
外周T细胞淋巴瘤累及唇部：一例罕见病例揭示诊断和治疗的关键点
Tooba Ali,Laraib Khan,Bilal Mazhar Qureshi et al.
Tooba Ali et al.
Peripheral T-cell lymphomas (PTCLs) represent a rare and heterogeneous group of lymphoproliferative disorders, accounting for about 10% of non-Hodgkin lymphomas. While PTCLs typically present at nodal sites, extra nodal involvement is uncom...
Feasibility and impact of knowledge-based automated radiotherapy treatment planning in low- and middle-income countries [0.03%]
知识为基础的自动化放疗计划在中低收入国家的应用前景及其影响
Awusi Kavuma,Solomon Kibudde,Yao Hao et al.
Awusi Kavuma et al.
Background and purpose: A high-quality treatment planning process is crucial in advanced radiotherapy techniques to ensure adequate dose to the target volume (TV) and sparing of organs at risk (OARs). This process often r...
Optimising multiple myeloma therapy in resource-limited settings: current perspectives and challenges [0.03%]
资源匮乏条件下优化多发性骨髓瘤治疗的现状及挑战
Bishal Tiwari,Samita Sapkota
Bishal Tiwari
Multiple myeloma (MM) represents a significant global health challenge, with its incidence and mortality rates steadily increasing over recent decades. This review critically examines the current landscape of MM management, with a specific ...
A survival analysis of paediatric acute lymphoblastic leukaemia patients at the Moroccan University Hospital Centre of Rabat [0.03%]
摩洛哥拉巴特大学医院中心儿童急性淋巴细胞白血病患者的生存分析
Bennani Mechita Nada,Messaoud Sara,Elboukhari Elmamoun Yousra et al.
Bennani Mechita Nada et al.
Introduction: Acute lymphoblastic leukaemia (ALL) is the most common childhood leukaemia and a significant cause of paediatric mortality worldwide. Morocco, as part of the World Health Organisation (WHO) Global Initiative...
Colorectal cancer care in Tanzania: an evaluation of clinical characteristics, treatment patterns and quality metrics at a national cancer referral hospital [0.03%]
坦桑尼亚的结直肠癌护理：一项国家癌症转诊医院临床特征、治疗模式和质量指标评估研究
Beatrice P Mushi,Summaiya Haddadi,Alita Mrema et al.
Beatrice P Mushi et al.
Background: Colorectal cancer (CRC) is a leading cause of cancer morbidity and mortality in Tanzania. Non-metastatic CRC is a potentially curable disease that requires multidisciplinary management. This study aimed to eva...
Clustering-based identification of immune-related gene signatures in hepatocellular carcinoma [0.03%]
基于聚类的肝细胞癌免疫相关基因标志物鉴定
Jyoti Brahmaiah,Usha Adiga,Alfred J Augustine et al.
Jyoti Brahmaiah et al.
Background: Hepatocellular carcinoma (HCC) is a complex malignancy influenced by genetic, epigenetic and immune-related factors. The tumour immune microenvironment plays a critical role in HCC progression and response to ...
CAR-T in relapsed refractory high-grade glioma and glioblastoma - who, what, when and how? [0.03%]
复发性难治性高级别胶质瘤和胶质母细胞瘤的CAR-T治疗：谁、何时及如何？
Deevyashali Parekh,Ansy H Patel,Areeb Khan et al.
Deevyashali Parekh et al.
Recurrent high-grade gliomas have a dismal prognosis. This review article aimed to explore and help answer the questions about which group of patients would benefit from chimeric antigen receptor therapy (CAR-T) cell therapy in this setting...